The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies. Value-seeking investors may find one of the most attractive opportunities developing in a different corner of the market. Biotech has spent much of the last four years in a bear market. Rising interest rates, weakening venture funding, and investor fatigue toward healthcare innovation caused valuations to fall sharply. However, many of the factors that harmed the sector are beginning to be reversed. Clinical trial activity is picking up. Global industry-sponsored trial starts stabilized at 5,318 in 2024, according to IQVIA, essentially returning to the 2019 pre-Covid level of 5,316, after declines in both 2022 and 2023. Activity by U.S. healthcare companies has increased from there, IQVIA said. Financing conditions are also stabilizing and large pharmaceutical companies are approaching a wave of patent expirations that will likely force them to acquire new drugs and technologies, which could also boost stock values. Importantly, investors do not have to speculate on risky clinical-stage companies to capitalize on the trend. Some of the industry's highest-quality companies trade at discounts to their historical valuations despite maintaining strong competitive positions and long-term growth prospects. While exact multiples will fluctuate based on earnings estimates, all three companies trade at valuations that appear reasonable relative to their competitive advantages, growth prospects, and historical trading ranges. Best Value: IQVIA If I were forced to pick a single stock, IQVIA would be my highest conviction idea. The company sits at the intersection of two powerful trends: growing spending on pharmaceutical research and the growing importance of healthcare data. IQVIA maintains one of the world's largest databases of healthcare information and provides clinical research services to drug developers around the world. That combination creates a business model that is extraordinarily difficult to replicate. Pharmaceutical companies rely on IQVIA data to design studies, identify patients, recruit trial participants, satisfy regulators, and increasingly train AI models. IQV Mountain 2016-07-08 IQVIA 10-Year Chart Think of the company as the toll collector on the drug development highway. What makes the opportunity particularly attractive is the valuation. Despite record accrual, improving demand trends, and significant AI opportunities, shares trade at a multiple that remains well below historical norms. The market appears to be pricing IQVIA as if spending on biotech research remains permanently subdued. If spending simply returns to normal growth rates, the stock could benefit from both earnings growth and multiple expansion. The Recovery Play: Danaher Danaher offers a different way to invest in biotech. Instead of developing drugs, the company provides the equipment, filtration systems and manufacturing technologies needed to produce them. Through its Cytiva and Pall businesses, Danaher has become one of the largest suppliers to the global biopharmaceutical industry. DHR Mountain 2016-07-08 DHR 10-Year Chart The key investment concept is switching costs. When a drug manufacturer validates a production process using a particular filtration platform or bioprocessing system, switching suppliers becomes expensive, time-consuming, and potentially risky. Regulatory requirements make those relationships even more lasting. As a result, Danaher enjoys one of the strongest installed bases in the healthcare sector. The company's stock has struggled because biotech clients spent much of the past two years working through excess inventory built up during the pandemic. Investors have treated that slowdown as evidence of structural weakness. However, biological medicines continue to gain share. Cellular and genetic therapies continue to advance. Pharmaceutical companies continue to invest in manufacturing capacity. The industry's long-term growth drivers remain intact. Danaher looks less like a company facing ongoing challenges and more like a dominant franchise emerging from a cyclical crisis. World-class biotech: Vertex Pharmaceuticals Vertex Pharmaceuticals is a true biotechnology company and arguably the highest quality drug developer in the industry. The company transformed the treatment of cystic fibrosis and now generates significant free cash flow from a franchise that continues to dominate its market. Unlike many biotech companies, Vertex does not need outside capital to fund its research. That financial strength gives management flexibility to invest aggressively in new opportunities. The company's product portfolio extends well beyond cystic fibrosis, encompassing pain management, kidney diseases, gene editing therapies and rare diseases. Several of these opportunities could become important growth drivers over the next decade. VRTX Mountain 2016-07-08 VRTX 10-Year Chart Vertex is not the cheapest stock among the three recommendations. However, investors will find a company with an exceptional balance sheet, industry-leading profitability and multiple avenues for growth. In an industry where many companies rely on favorable capital markets, Vertex stands out as a self-funded innovator. Biotech may be poised to outperform biotech investors who have heard versions of this argument before. The sector has looked cheap at various times since 2021, only to disappoint. History explains much of today's skepticism. The difference now is that several important variables appear to be moving in the same direction. Funding markets are healthier. Clinical activity is improving. AI is accelerating drug discovery and development. Meanwhile, major pharmaceutical companies face increasing pressure to replace revenue that will disappear as key patents expire. Those forces should support greater investment throughout the biotech industry. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO PURCHASE ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS OF A GENERAL NATURE AND DOES NOT REFLECT THE UNIQUE PERSONAL CIRCUMSTANCES OF ANY INDIVIDUAL. THE ABOVE CONTENT MAY NOT BE APPROPRIATE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISION, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here to view the full disclaimer.
